Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters
| Autor: | Birgit Svenstrup, Johannes D. Veldhuis, Sanne Fisker, Marianne Andersen, Jens Sandahl Christiansen, Claus Højbjerg Gravholt, Paul Bennett, Jens Otto Lunde Jørgensen, Jens Juel Christiansen |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Dehydroepiandrosterone Biology Statistics Nonparametric Insulin-like growth factor Endocrinology Double-Blind Method Internal medicine medicine Adrenal insufficiency Humans Testosterone Insulin-Like Growth Factor I Receptor Cross-Over Studies Estrogens Receptors Somatotropin Middle Aged Androgen medicine.disease Crossover study Growth hormone secretion Insulin-Like Growth Factor Binding Protein 3 Case-Control Studies Growth Hormone Female Secretory Rate Adrenal Insufficiency Half-Life |
| Zdroj: | Clinical Endocrinology. 60:461-469 |
| ISSN: | 1365-2265 0300-0664 |
| DOI: | 10.1111/j.1365-2265.2004.01998.x |
| Popis: | Objective In women, GH secretion is strongly influenced by oestrogen status, whereas the role of androgens is unclear. We, therefore, examined GH secretory dynamics during low vs. normalized androgen levels in women with adrenal failure. Patients Ten females with adrenal failure (AF), mean age of 42 years (range 22-54 years). Design The effects of 8 days of oral dehydroepiandrosterone (DHEA; 50 mg/day) were studied in a double-blind placebo-controlled, cross-over design. A control group of healthy women was studied once without any treatment. Measurements Before and after each treatment period, blood was sampled for measurement of androgens, IGF-I, IGFBP-3 and GHBP. A 24-h GH profile with measurements every 20 min was performed at the end of each period. Results DHEA supplementation normalized the mean circulating levels of testosterone and androgen precursors. The secretory pattern of GH was unaltered during DHEA [placebo vs. DHEA; half-life 22.83 +/- 1.24 vs. 21.45 +/- 1.19 (min), P = 0.429; pulse frequency 9.9 +/- 0.7 vs. 10.5 +/- 0.5 (/24 h), P = 0.502; total production rate 62.27 +/- 13.44 vs. 52.61 +/- 7.06 (microg/l/day), P = 0.317]. Subgroup analysis, however, indicated that DHEA treatment increased GH secretion in patients not receiving oestrogen (n = 5), whereas the opposite was observed among patients receiving exogenous oestrogen derivatives (n = 5). Compared to the control group (CON), GH half-life was longer in AF (half-life CON: 16.48 +/- 0.91, P = 0.001). The additional features of GH secretion were similar. Unexpectedly, the levels of IGF-I, IGFBP-3 and GHBP were elevated in the patients as compared to controls, without significant effects of DHEA [AF vs. CON. IGF-I: 186 +/- 20 vs. 144 +/- 7 (microg/l), P = 0.04; IGFBP-3: 5196 +/- 224 vs. 3687 +/- 212 (microg/l), P = 0.001; GHBP: 2.27 +/- 0.25 vs. 1.41 +/- 0.13 (nmol/l), P = 0.002]. Conclusion (1) Short-term DHEA administration in women with adrenal failure normalizes the circulating levels of androgens without uniformly affecting the GH-IGF axis; (2) The observation that exogenous oestradiol may mask a stimulatory effect of DHEA on GH secretion merits future investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text